- Home
- AXSM
as 11-21-2024 2:31pm EST
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 4.4B | IPO Year: | 2015 |
| Target Price: | $124.93 | AVG Volume (30 days): | 531.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $59.09 - $105.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | $338,457,000 | Revenue Growth: | 51.47% |
| Revenue Growth (this year): | 40.67% | Revenue Growth (next year): | 69.27% |
Stock Insider Trading Activity of Axsome Therapeutics Inc. (AXSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saad Mark E | AXSM | Director | Sep 11 '24 | Sell | $91.31 | 11,016 | $1,005,870.96 | 10,002 |
Latest Axsome Therapeutics Inc. News
AXSM Breaking Stock News: Dive into AXSM Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
Thomson Reuters StreetEvents
8 days ago
Q3 2024 Axsome Therapeutics Inc Earnings Call
Motley Fool
9 days ago
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
GuruFocus.com
9 days ago
Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains
GlobeNewswire
9 days ago
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
13 days ago
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
Zacks
16 days ago
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
GlobeNewswire
23 days ago
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
Compare AXSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXSM Axsome Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.